基础胰岛素治疗的2型糖尿病患者转换为每周一次胰岛素icodec与每日一次德谷胰岛素的比较(ONWARDS 2):一项3a期、随机、开放标签、多中心、治疗达标试验
ONWARDS 2是一项为期26周的3a期随机开放标签多中心治疗达标试验,在9个国家71个中心纳入526例基础胰岛素治疗的2型糖尿病患者,1:1随机接受每周一次icodec或每日一次德谷胰岛素。第26周时icodec组HbA1c降幅优于德谷胰岛素组(7.20% vs 7.42%),估计治疗差异-0.22个百分点(95%CI -0.37至-0.08),非劣效性和优效性均成立,icodec组体重增加更明显,2级或3级低血糖事件率数值上更高但未达统计学显著。
要点
- 每周一次icodec在降低HbA1c方面非劣效且统计学优于每日一次德谷胰岛素。
- icodec组体重变化+1.40 kg,德谷胰岛素组-0.30 kg,估计治疗差异1.70 kg。
- 2级或3级低血糖事件率icodec组0.73 vs 德谷胰岛素组0.27每患者年,估计率比1.93(95%CI 0.93至4.02),未达统计学显著。
核心结论
- 在基础胰岛素治疗的2型糖尿病成人中,每周一次icodec相比每日一次德谷胰岛素在26周时HbA1c降低方面显示非劣效性和统计学优效性,并伴有适度体重增加。
- 低血糖总体发生率低,icodec组2级或3级低血糖事件率数值上高于德谷胰岛素组但未达统计学显著。
研究设计与样本
- 26周、随机、开放标签、活性对照、多中心、治疗达标3a期试验,在9个国家71个中心开展。
- 共筛查635例,109例不合格或退出,526例随机分配至icodec组(n=263)或德谷胰岛素组(n=263)。
- 纳入标准为每日一次或每日两次基础胰岛素治疗(联用或不联用非胰岛素降糖药)血糖控制不佳的2型糖尿病患者。
- 主要结局为基线至第26周HbA1c变化,非劣效界值为0.3个百分点。
主要发现
- HbA1c从基线icodec组8.17%(65.8 mmol/mol)、德谷胰岛素组8.10%(65.0 mmol/mol)降至第26周icodec组7.20%(55.2 mmol/mol) vs 德谷胰岛素组7.42%(57.6 mmol/mol)。
- 估计治疗差异为-0.22个百分点(95%CI -0.37至-0.08)或-2.4 mmol/mol(95%CI -4.1至-0.8),非劣效性p<0.0001,优效性p=0.0028。
- 体重自基线至第26周估计平均变化icodec组+1.40 kg vs 德谷胰岛素组-0.30 kg,估计治疗差异1.70 kg(95%CI 0.76至2.63)。
- 2级或3级低血糖合并事件率icodec组0.73 vs 德谷胰岛素组0.27每患者年暴露,估计率比1.93(95%CI 0.93至4.02)。
- icodec组262例中161例(61%) vs 德谷胰岛素组263例中134例(51%)发生不良事件;严重不良事件分别为22例(8%) vs 16例(6%)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Insulin icodec (icodec) is a once-weekly basal insulin currently under development. ONWARDS 2 aimed to assess the efficacy and safety of once-weekly icodec versus once-daily insulin degludec (degludec) in basal insulin-treated type 2 diabetes. METHODS: This 26-week, randomised, open-label, active-controlled, multicentre, treat-to-target phase 3a trial was conducted in 71 sites in nine countries. Eligible participants with type 2 diabetes inadequately controlled on once-daily or twice-daily basal insulin, with or without non-insulin glucose-lowering agents, were randomly assigned (1:1) to once-weekly icodec or once-daily degludec. The primary outcome was change from baseline to week 26 in HbA1c; the margin used to establish non-inferiority of icodec compared with degludec was 0·3 percentage points. Safety outcomes (hypoglycaemic episodes and adverse events) and patient-reported outcomes were also assessed. The primary outcome was evaluated in all randomly assigned participants; safety outcomes were evaluated descriptively based on all randomly assigned participants who received at least one dose of trial product, with statistical analyses based on all randomly assigned participants. This trial is registered with ClinicalTrials.gov, NCT04770532, and is now complete. FINDINGS: Between March 5 and July 19, 2021, 635 participants were screened, of whom 109 were ineligible or withdrew, and 526 were randomly assigned to icodec (n=263) or degludec (n=263). From a mean baseline of 8·17% (icodec; 65·8 mmol/mol) and 8·10% (degludec; 65·0 mmol/mol), HbA1c was reduced to a greater extent with icodec than degludec (7·20% vs 7·42% [55·2 vs 57·6 mmol/mol], respectively) at week 26. This translates to an estimated treatment difference (ETD) of -0·22 percentage points (95% CI -0·37 to -0·08) or -2·4 mmol/mol (95% CI -4·1 to -0·8), demonstrating non-inferiority (p<0·0001) and superiority (p=0·0028). The estimated mean change from baseline to week 26 in bodyweight was +1·40 kg for icodec and -0·30 kg for degludec (ETD 1·70 [95% CI 0·76 to 2·63]). Overall rates of combined level 2 or level 3 hypoglycaemia were less than one event per patient-year of exposure for both groups (0·73 [icodec] vs 0·27 [degludec]; estimated rate ratio 1·93 [95% CI 0·93 to 4·02]). Overall, 161 (61%) of 262 participants receiving icodec and 134 (51%) of 263 participants receiving degludec experienced an adverse event; 22 (8%) and 16 (6%), respectively, experienced a serious adverse event. One serious adverse event (degludec) was assessed as being possibly related to treatment. No new safety issues were identified in relation to icodec compared with degludec in this trial. INTERPRETATION: Among adults with basal insulin-treated type 2 diabetes, treatment with once-weekly icodec versus once-daily degludec demonstrated non-inferiority and statistical superiority in HbA1c reduction after 26 weeks, associated with modest weight gain. Overall rates of hypoglycaemia were low, with numerically but not statistically significantly higher event rates of level 2 or level 3 hypoglycaemia with icodec versus degludec. FUNDING: Novo Nordisk.
引用
- Philis-Tsimikas A, Asong M, Franek E, et al. Switching to once-weekly insulin icodec versus once-daily insulin degludec in individuals with basal insulin-treated type 2 diabetes (ONWARDS 2): a phase 3a, randomised, open label, multicentre, treat-to-target trial. Lancet Diabetes Endocrinol. 2023. PMID: 37148899. doi:10.1016/S2213-8587(23)00093-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。